Weight
Tesamorelin
Growth
36
Amino acids
Molecular weight
Peptide
Type
Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.
Top researched benefits
Overview of Tesamorelin
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.
weight loss
- FDA-approved indication showing 15-20% visceral fat reduction in clinical trials.
- Unique mechanism that reduces dangerous visceral fat while sparing subcutaneous fat.
- Maintained weight loss with continuous treatment over 52+ weeks in clinical studies.
metabolic
- 12.3% reduction in triglyceride levels.
- 7.2% improvement in cholesterol markers.
- 37% liver fat reduction over 12 months.
body composition
- Preserves lean muscle mass during fat loss.
- 26% increase in IGF-1 levels.
Typical Dose
1-2mg daily (FDA-approved: 2mg for HIV lipodystrophy)
Frequency
Once daily (evening preferred for GH rhythm)
Cycle Duration
Continuous therapy for maintained benefits
Storage
Powder: 20-25°C. Egrifta SV: use immediately. Egrifta WR: room temp up to 7 days
Chemical Makeup
Key benefits
FDA-approved formulation
Selective visceral fat targeting (15-20% reduction)
Proven clinical efficacy
Standardized dosing
37% liver fat reduction in NAFLD
Preserved subcutaneous fat
Community interest
This peptide is still gaining traction in the community.
GHRH Analog | Visceral Fat Reduction
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoTesamorelin Molecular Information
View the scientifc details of Tesamorelin.
36
Amino Acids
Tesamorelin
Tyr
Tyr
Position 1
Pro
Pro
Position 2
Ser
Ser
Position 3
Lys
Lys
Position 4
Pro
Pro
Position 5
Asp
Asp
Position 6
Asn
Asn
Position 7
Pro
Pro
Position 8
Gly
Gly
Position 9
Glu
Glu
Position 10
Asp
Asp
Position 11
Ala
Ala
Position 12
Pro
Pro
Position 13
Ala
Ala
Position 14
Glu
Glu
Position 15
Asp
Asp
Position 16
Leu
Leu
Position 17
Ala
Ala
Position 18
Arg
Arg
Position 19
Tyr
Tyr
Position 20
Tyr
Tyr
Position 21
Ser
Ser
Position 22
Ala
Ala
Position 23
Leu
Leu
Position 24
Arg
Arg
Position 25
His
His
Position 26
Tyr
Tyr
Position 27
Ile
Ile
Position 28
Asn
Asn
Position 29
Leu
Leu
Position 30
Ile
Ile
Position 31
Thr
Thr
Position 32
Arg
Arg
Position 33
Glu
Glu
Position 34
Arg
Arg
Position 35
Tyr
Tyr
Position 36
Molecular Weight
4255DaChain Length
36Amino AcidsType
PeptideTesamorelin Protocols
Subcutaneous injection to abdomen (avoid navel ±2 inches). Evening injection preferred for GH circadian rhythm alignment.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| HIV Lipodystrophy (FDA-approved) | 1.4 | 1 week range | SubQ |
| Visceral Fat Reduction | 2 | 1 week range | SubQ |
| Anti-aging/Body Composition | 1 | 5 week range | SubQ |
| NAFLD Treatment | 2 | 12 week range | SubQ |
| Cognitive Enhancement | 1 | 20 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Allow vial to reach room temperature
- Egrifta SV: Add 0.5mL sterile water to 2mg vial - use immediately
- Egrifta WR: Add 1.3mL bacteriostatic water to 11.6mg vial - stable 7 days
- Gently swirl (don't shake vigorously)
- Withdraw appropriate dose (~0.35mL for 1.4mg)
- Inject SubQ, rotating sites
- Store reconstituted WR at room temperature up to 7 days
Tesamorelin Cycle
The Tesamorelin Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- IGF-1 levels begin to rise, possible mild water retention or joint discomfort
- Week 4-6
- Early metabolic changes; improved energy/sleep
- Week 8-12
- Visible visceral fat reduction begins, waist circumference may decrease
- Week 12-26
- Peak effects achieved with significant body composition improvements
Dosing tools
Tesamorelin Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Tesamorelin
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Tesamorelin vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Tesamorelin
- Dosing
- 1-2mg daily (FDA-approved: 2mg for HIV lipodystrophy)
- Dosing Frequency
- Once daily (evening preferred for GH rhythm)
- Cycle Duration
- Continuous therapy for maintained benefits
- Storage
- Powder: 20-25°C. Egrifta SV: use immediately. Egrifta WR: room temp up to 7 days
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Side effects
Monitor: Be careful when combining Tesamorelin with Ipamorelin, Sermorelin.
Contraindications
Active malignancy
Pituitary disorders
Pregnancy
Stop signs
Development of diabetes or severe glucose intolerance (HbA1c ≥6.5%)
Signs of malignancy
Severe hypersensitivity reactions
Excessive IGF-1 elevation (>2 SD above normal) with acromegaly symptoms
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
TesamorelinResearch References
Tesamorelin is a fda approved compound
Tesamorelin
Tesamorelin is a fda approved compound
LIPO-010 FDA Pivotal Trial
Significant visceral adipose tissue reduction (-24 ± 41 cm² vs +2 ± 35 cm² placebo, p < 0.001) in HIV patients over 26 weeks.
2010
CTR-1011 Extended Safety Study
69% achieved ≥8% VAT reduction vs 33% placebo at 26-52 weeks.
2011
NAFLD Treatment Trial
37% liver fat reduction over 12 months with fibrosis progression prevention.
2019
Cognitive Enhancement Study
Improved executive function and verbal memory in healthy elderly and mild cognitive impairment cohorts at 1mg daily.
2012